Single or dual antiplatelet therapy after PCI

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• The optimal duration of dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) implantation is not definitively established.
• Initial DAPT protocols were short (2 months), but extended to 1 year based on limited data, influencing clinical guidelines.
• Heterogeneity in trial endpoints, randomization timing, and bleeding definitions complicates evidence interpretation.

Purpose of the Study:

• To review current evidence on DAPT duration, bleeding risks, and adverse cardiac events after DES implantation.
• To discuss the limitations and pitfalls in interpreting existing clinical trials.
• To highlight ongoing trials investigating single antiplatelet therapy post-DES.

Main Methods:

• Systematic review of existing clinical trials and guidelines.
• Analysis of data regarding DAPT duration, bleeding events, and cardiac outcomes.
• Discussion of pharmaceutical advancements in antiplatelet agents.

Main Results:

• Evidence comparing abbreviated (<6 months) and prolonged (>12 months) DAPT is limited and heterogeneous.
• Newer ADP-receptor antagonists have shifted focus towards single antiplatelet therapy efficacy.
• The optimal balance between preventing stent thrombosis and minimizing bleeding remains a challenge.

Conclusions:

• The optimal DAPT duration post-DES requires further clarification due to inconsistent trial data.
• Ongoing trials are crucial for evaluating the safety and efficacy of single antiplatelet therapy.
• Personalized antiplatelet strategies may be necessary based on individual patient risk profiles.